Use of amnion‐derived cellular cytokine solution for the treatment of gingivitis: A 2‐week safety, dose‐ranging, proof‐of‐principle randomized trial

Hastürk, Hatice; Steed, David L.; Tosun, Emre; Martins, Melissa; Floros, Constantinos; Nguyen, Daniel; Stephens, Danielle; Cugini, MaryAnn; Starr, Jacqueline R.; Dyke, Thomas E. Van

doi:10.1002/jper.20-0800

Cited by 6 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DCFH staining was used to detect cellular ROS levels [ 28 ]. Almost no green fluorescence was detected in the cells of blank control group and DhHP-6 group.…”

Section: Resultsmentioning

confidence: 99%

Deuterohemin-Ala-His-Thr-Val-Glu-Lys (DhHP-6) Mimicking Enzyme as Synergistic Antioxidant and Anti-Inflammatory Material for Periodontitis Therapy

et al. 2022

View full text Add to dashboard Cite

Periodontitis is an inflammatory disease induced by plaque microorganisms. In the clinic, antibiotic assistant periodontal mechanical therapy is the most effective therapy for the treatment of periodontitis. However, the drug resistance of the antibiotics and the repeated coming and diminishing of the disorder of oxidation–reduction balance in the inflammatory tissue could not meet the high requirements for periodontic health control in long periods. Deuterohemin-ala-his-thr-val-glu-lys (DhHP-6) is a biomimetic oxidase-mimicking enzyme that simulates the reactive oxygen radical scavenger function of heme by synthesizing the new molecular material following the key structure and amino acid sequence of heme. In this article, we report the antioxidant and anti-inflammatory properties of DhHP-6 by building a inflammatory model for human gingival fibroblasts (HGFs) stimulated by lipolysaccharide (LPS) and its effects on periodontitis in Wistar rats. DhHP-6 reduced the oxidative stress of HGFs by increasing the amount of the reductase species of glutathione (GSH) and catalase (CAT) while decreasing the amount of oxidase species of malonaldehyde (MDA) and reactive oxygen species (ROS). DhHP-6 had a dose-dependent protective effect on alveolar bone absorption in rats with periodontitis, enhanced antioxidant capacity, and reduced inflammation. As determined by Micro-CT scanning, DhHP-6 reduced alveolar bone loss and improved the bone structure of the left maxillary first molar of rats. There were no obvious morphological and histological differences in the rat organs with or without DhHP-6 treatment. These results suggest that DhHP-6 can be used to treat periodontitis by increasing the expression levels of antioxidant enzymes and antioxidants in systemic and local tissues, thereby reducing levels of oxidation products and cyto-inflammatory factors. The synergistic antioxidant and anti-inflammatory effects of DhHP-6 suggest that there are promising applications of this biomimetic enzyme molecular material for the next generation of agents for periodontitis therapy.

show abstract

“…DCFH staining was used to detect cellular ROS levels [ 28 ]. Almost no green fluorescence was detected in the cells of blank control group and DhHP-6 group.…”

Section: Resultsmentioning

confidence: 99%

Deuterohemin-Ala-His-Thr-Val-Glu-Lys (DhHP-6) Mimicking Enzyme as Synergistic Antioxidant and Anti-Inflammatory Material for Periodontitis Therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A recent study showed periodontitis to predict an increased risk of ischemic heart disease and death in the long-term follow up [ 29 ]. Also another study showed that periodontal inflammation is independently associated with the risk of future cardiovascular events [ 30 ]. Thus, reducing periodontal inflammation might also reduce the risk of new cardiovascular events and fatal course in individuals after HTx or with LVAD.…”

Section: Discussionmentioning

confidence: 99%

Comparison of periodontal parameters between patients with ischemic and dilative cardiomyopathy

Ziebolz

Binner

Reuschel

et al. 2021

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background This cross-sectional study aimed in the comparison of periodontal parameters, number of remaining teeth and oral behaviour between patients with ischemic- (ICM) and non-ischemic dilative cardiomyopathy (DCM). Methods Patients with HF from the Department for Cardiac Surgery at the Heart Center Leipzig were included. The two groups (ICM and DCM) were composed by matching according to age, gender and smoking habits. All participants received a comprehensive periodontal examination, including a periodontal probing on six measurement points of each tooth. Results A total of 226 patients (n = 113 each group) was included. Patients in DCM group used interdental cleaning significantly more often than ICM (23.9% vs. 12.5%, p = 0.04). The majority of patients in both groups (ICM: 83.6%, DCM: 84.6%, p = 0.23) were diagnosed with stage III–IV periodontitis. Periodontal parameters were comparable between groups (p > 0.05). Variance analysis revealed no influence of the group (ICM vs. DCM) on the number of remaining teeth (p = 0.16), periodontitis stage (p = 0.27) or the periodontal inflamed surface area (p = 0.62). Conclusions Patients with severe HF show high periodontal burden, without any differences between ICM and DCM group. Therefore, increased attention should be payed to periodontal health of patients with severe heart disease, irrespective of their underlying disease.

show abstract

Use of amnion‐derived cellular cytokine solution for the treatment of gingivitis: A 2‐week safety, dose‐ranging, proof‐of‐principle randomized trial

Hastürk¹,

Steed²,

Tosun³

et al. 2021

Journal of Periodontology

Self Cite

View full text Add to dashboard Cite

Biotherapeutics, owns stocks and filed multiple patents on ST266. Dr. Van Dyke has been a paid advisor and owns stocks in Noveome Biotheraputics. Authors' Contribution: HH substantially contributed to conception and design, acquisition, analysis, and interpretation of data; drafted and critically revised the article for important intellectual content. DS contributed to conception and design, analysis and interpretation of the data, critically revised the article. ET and TVD critically revised the manuscript with important intellectual contribution. MM and CF performed data and sample collection and data entry. MC supervised randomization, study execution and data acquisition. DN and DS performed analysis of biological specimens and critically revised the analytical sections. JS performed statistical analyses and contributed to interpretation of the results. All authors approved the final version of the article and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Word count: 5,146; Number of figures: 3; Number of tables: 3; Number of references: 47 Running title: Amnion-Derived Cytokine Solution for Gingivitis Treatment One sentence summary: In this Phase 1 trial oral topical application of amnion-derived cytokine solution, now termed ST266, significantly reduced the gingival inflammation in both tissue and GCF as shown by decreased level of proinflammatory cytokines.

show abstract

Use of amnion‐derived cellular cytokine solution for the treatment of gingivitis: A 2‐week safety, dose‐ranging, proof‐of‐principle randomized trial

Cited by 6 publications

References 39 publications

Deuterohemin-Ala-His-Thr-Val-Glu-Lys (DhHP-6) Mimicking Enzyme as Synergistic Antioxidant and Anti-Inflammatory Material for Periodontitis Therapy

Deuterohemin-Ala-His-Thr-Val-Glu-Lys (DhHP-6) Mimicking Enzyme as Synergistic Antioxidant and Anti-Inflammatory Material for Periodontitis Therapy

Comparison of periodontal parameters between patients with ischemic and dilative cardiomyopathy

Use of amnion‐derived cellular cytokine solution for the treatment of gingivitis: A 2‐week safety, dose‐ranging, proof‐of‐principle randomized trial

Contact Info

Product

Resources

About